SLU-PP-332
pan-ERR agonist (not a peptide)
SLU-PP-332 is a synthetic small molecule — not a peptide — that activates the estrogen-related receptors, studied in animals as an “exercise mimetic”.
Regulatory status: Not a medicine. It has never been given to a person in a published study and is not approved anywhere.
Default vial
10 mg
Default mix
2 mL
Reported range
No published human dose
Draw (U-100)
10 u
Not a peptide — a synthetic small molecule that activates the estrogen-related receptors, studied as an 'exercise mimetic'. All published work is animal and cell research; no human has been dosed in a published study.
Where these numbers come from
No published study reports a dose for this compound in people. The figures here exist only so the calculator can run — they are not a recommendation. SLU-PP-332 is a small molecule, not a peptide, and every published study is in animals or cells.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome, J Pharmacol Exp Ther 2024
- Synthetic ERRα/β/γ agonist induces an acute aerobic exercise response and enhances exercise capacity, ACS Chem Biol 2023
Reviewed October 2026
What it is
- A small molecule, not a peptide. Pep-Tidy lists it because it is sold alongside peptides, not because it is one.
- A pan-agonist at the estrogen-related receptors ERRα, ERRβ and ERRγ, which help govern mitochondrial and oxidative metabolism.
- Described in the literature as an exercise mimetic: the aim is to switch on some of the genetic programme that endurance exercise activates.
- A research compound, studied orally in rodents.
How it is described to act
- 1
Given orally in animal studies; no human pharmacokinetics are published.
- 2
Reported to reach tissues with high ERR expression, particularly skeletal muscle and heart.
- 3
Proposed to drive a transcriptional programme that increases mitochondrial function and fatty acid oxidation.
- 4
In mice this was associated with greater running capacity and changes in metabolic measures.
What the research has looked at
Animal and cell studies
- Investigators reported that a synthetic ERR agonist improved measures of metabolic syndrome in mice (J Pharmacol Exp Ther, 2024).
- In an earlier study the compound was reported to induce an acute aerobic exercise response and increase exercise capacity, in an ERRα-dependent way (ACS Chem Biol, 2023).
- Related pan-ERR agonists have been studied in heart failure models (Circulation, 2023) and in the ageing kidney (Am J Pathol, 2023).
- A 2025 pilot study treated myoblasts taken from inactive women in culture — human cells, not human dosing.
Doping context
- A 2026 analytical paper characterised SLU-PP-332 and the related SLU-PP-915 specifically as compounds with doping potential, developing methods to detect them.
- That work exists because the compound is already circulating outside research, not because it has been approved for anything.
Strength of evidence: Preclinical evidence only
Every published study is in animals or cells. No human has been dosed in a published study, so nothing is known about effect, dose or safety in people.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- There is no human safety data.
- ERR receptors are expressed throughout the body, including the heart. A systemic pan-agonist acts everywhere those receptors are, and no published work has assessed what that does over time in a person.
- Anti-doping laboratories now screen for it, so it is a testing risk for anyone competing.
References
- 1.A Synthetic ERR Agonist Alleviates Metabolic Syndrome, J Pharmacol Exp Ther (2024)
- 2.Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity, ACS Chem Biol (2023)
- 3.In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential, Rapid Commun Mass Spectrom (2026)
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
SLU-PP-332 questions people ask
How do you reconstitute SLU-PP-332?
A common starting point for a 10 mg vial of SLU-PP-332 is 2 mL of bacteriostatic water, which gives 5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of SLU-PP-332 is one dose?
At 5 mg per mL, that works out to about 10 units on a U-100 insulin syringe for a 500 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for SLU-PP-332?
Published and community sources describe No published human dose, oral, every day, typically run 4 weeks on and 2 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should SLU-PP-332 be stored?
Lyophilized SLU-PP-332 vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.